E-ISSN: 1019-5157
ISSN: 2651-5024
Review
[alpha][alpha][alpha]Molecular And Genetic Characterization Of Atypical And Anaplastic Meningioma Implications For Prognosis And Targeted Therapy
Naeem ul Haq✉ ,
Rizwan Ali ,
Musawer khan ,
Muhmmand Ishaq ,
Syed Nasir Shah ,
akram ullah
DOI: 10.5137/1019-5149.JTN.49866-25.3
Article in Press
Corresponding Author:
Naeem ul Haq (drnaeem@bkmc.edu.pk)
Abstract
Objectives: To characterize the molecular and genetic landscape of atypical and anaplastic meningiomas and assess their prognostic significance.
Methods: This retrospective study was carried from January 2024 to January 2025. Whole-exome sequencing, RNA sequencing, and DNA methylation profiling were carried out on atypical and anaplastic meningioma specimens. Further important biomarkers were scrutinized using immunohistochemistry, including, but not limited to, Ki-67, p53, and PR. Bioinformatics methods were employed to study the correlations among recurrence, survival, and molecular changes. Statistical analyses involved t-tests for continuous values and KaplanMeier survival curves to assess outcomes.
Results 50 patients (25 atypical and 25 anaplastic) were aged 58.4 years (mean age). The male-to-female ratio was 1:1.3. There was a decreased survival of anaplastic meningiomas (p = 0.038). Typical mutations: NF2 (47%), deletion of CDKN2A/B (29%), TERT promoter deletions (18%). Methylation profiling was associated with prognosis.
Conclusion: Atypical and an plastic meningiomas differ, with molecular and genetic profiles indicating various changes linked to prognosis. The application of these findings into clinical care can positively affect the risk stratification and the development of targeted therapies. It is reasonable to develop this direction further and analyze the validity of these biomarkers and be able to gauge their usefulness in predicting therapeutic response and survival.
Methods: This retrospective study was carried from January 2024 to January 2025. Whole-exome sequencing, RNA sequencing, and DNA methylation profiling were carried out on atypical and anaplastic meningioma specimens. Further important biomarkers were scrutinized using immunohistochemistry, including, but not limited to, Ki-67, p53, and PR. Bioinformatics methods were employed to study the correlations among recurrence, survival, and molecular changes. Statistical analyses involved t-tests for continuous values and KaplanMeier survival curves to assess outcomes.
Results 50 patients (25 atypical and 25 anaplastic) were aged 58.4 years (mean age). The male-to-female ratio was 1:1.3. There was a decreased survival of anaplastic meningiomas (p = 0.038). Typical mutations: NF2 (47%), deletion of CDKN2A/B (29%), TERT promoter deletions (18%). Methylation profiling was associated with prognosis.
Conclusion: Atypical and an plastic meningiomas differ, with molecular and genetic profiles indicating various changes linked to prognosis. The application of these findings into clinical care can positively affect the risk stratification and the development of targeted therapies. It is reasonable to develop this direction further and analyze the validity of these biomarkers and be able to gauge their usefulness in predicting therapeutic response and survival.
Keywords
Meningioma
genetics
prognosis
treatment